Patients harboring homozygous A/A genotype in rs11615 of ERCC1 showed significantly higher risk of neutropenia (any grade) during chemotherapy than heterozygous patients A/G (P = .0133; χ2 = 6.12; Figure 5). This evidence concerns the gene ERCC1 and Decreased total neutrophil count.